Market News AIOpen the app

EDIT stock news · Editas Medicine, Inc.

Stories about Editas Medicine, Inc. (EDIT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for EDIT

Follow Editas Medicine, Inc. (EDIT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EDIT
Free on the App Store and Google Play, or on the web.
  1. Oct 8, 2026, 7:10 AM ET · Market

    Editas Medicine says it got the green light to start its first human trial for EDIT-401.

    Good for EDIT

    Editas received approval to start its first human trial of EDIT-401 in Australia. Promising monkey results support the program, but human safety and benefit remain unknown, making the news positive for EDIT.

  2. Sep 23, 2026, 10:10 AM ET · Market

    TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine, and other big stocks climbed on Wednesday.

    Good for EDIT

    Editas Medicine was upgraded from Neutral to Buy with a $5 price target, indicating an analyst expects better performance than before.

  3. Sep 23, 2026, 9:29 AM ET · Opinion

    An analyst is feeling positive about Editas Medicine and shares four company upgrades for Wednesday.

    Good for EDIT

    Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, which increases analyst support relative to the $2.92 close.